CRISPR Therapeutics AG (NASDAQ:CRSP) price onThursday, Jun 03, dropped -4.28% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $109.83.
A look at the stock’s price movement, the close in the last trading session was $114.74, moving within a range at $109.68 and $114.99. The beta value (5-Year monthly) was 2.25 while the PE ratio in trailing twelve months stood at 0. Turning to its 52-week performance, $220.2 and $58.02 were the 52-week high and 52-week low respectively. Overall, CRSP moved -5.1% over the past month.
CRISPR Therapeutics AG’s market cap currently stands at around $8.34 Billion, with investors looking forward to this quarter’s earnings report slated for Jul 26, 2021- Jul 30, 2021. The company has a Forward Dividend ratio of 0, with its dividend yield at 0%. As such, investors might be keen on a downside in the stock’s price ahead of the scheduled earnings report. Analysts project the company’s earnings per share (EPS) to be $3.26, which has seen fiscal year 2021 EPS growth forecast to increase to -$0.82 and about -$6.29 for fiscal year 2022. Per the data, EPS growth is expected to be -0.84% for 2021 and 6.67% for the next financial year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was 1 upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that CRSP is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
21 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 5 analyst(s) rate the stock as a Hold, 14 recommend CRSP as a Buy and none give it an Outperform rating. Meanwhile, none analyst(s) rate the stock as Underperform and 2 say it is a Sell. As such, the average rating for the stock is Overweight which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
The technical evaluation for the stock shows the PEG ratio is 0, with CRSP’s current price about -1.33% and -6.61% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 41.96, while 7-day volatility ratio is 4.23% and 5.43% in the 30-day chart. Further, CRISPR Therapeutics AG (CRSP) has a beta value of 2.25, and an average true range (ATR) of 6.11. Analysts have given the company’s stock an average 52-week price target of $158.83, forecast between a low of $55 and high of $220. Looking at the price targets, the low is -49.92% off current price level while to achieve the yearly target high, price needs to move +100.31%. Nonetheless, investors will most likely welcome a +50.23% jump to $165 which is the analysts’ median price.
In the market, a comparison of CRISPR Therapeutics AG (CRSP) and its peers suggest the former has performed considerably weaker. Data shows CRSP’s intraday price has changed -4.28% in last session and +69.1% over the past year. Comparatively, Bristol-Myers Squibb Company (BMY) has moved +0.17% on the day and only +7.62% in the past 12 months. Looking at another peer, we see that Amgen Inc (AMGN) price has surged 0.25% on the day. However, the stock is 6.67% off its price a year ago. Moreover, Gilead Sciences Inc (GILD) is also down -4.28% in trading on the day while keeping an uptrend of 69.1% over the past year. If we look at the PE ratio, we find that CRISPR Therapeutics AG’s ratio stands at 0 compared to Bristol-Myers Squibb Company’s 0 and Amgen Inc’s 19.52. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are down -0.36% and down -0.07% respectively in the last trading.
If we refocus on CRISPR Therapeutics AG (NASDAQ:CRSP), historical trading data shows that trading volumes averaged 785.78 Million over the past 10 days and 1.63 Million over the past 3 months. The company’s latest data on shares outstanding shows there are 75.77 Million shares.
As per Thomson Reuters, 12.93% of CRISPR Therapeutics AG’s shares are in the hands of company insiders while institutional holders own 64.07% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 4.25 Million on April 14, 2021, giving us a short ratio of 3.01. The data shows that as of April 14, 2021 short interest in CRISPR Therapeutics AG (CRSP) stood at 5.61% of shares outstanding, with shares short rising to 4.22 Million registered in March. Current price change has pushed the stock -28.27% YTD, which shows the risk of further decline is there. It is this reason that could see investor optimism for the CRSP stock might rise going into the next quarter.